Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387071 · ClinicalTrials.gov registry record · Phase 1
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04387071 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 2 participants.
The verdict
NCT04387071, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in a protein, known as a virus-like particle (VLP). VLPs are detected and processed by cells of the immune system. The DNA contained in CMP-001 activates the immune system and recruit cells of the immune system to the tumor. INCAGN01949 is an antibody, a type of protein, which has been shown to stimulate the immune system. Injecting CMP-001 and INCAGN01949 directly into the tumor may work against tumor cells to slow tumor growth by causing tumor cells to die.
Interventions
- BIOLOGICAL Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
- DRUG VLP-encapsulated TLR9 Agonist CMP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387071
The ClinicalTrials.gov registry entry for NCT04387071 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 is the first listed.
NCT04387071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04387071 about?
NCT04387071 is a clinical study titled "CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma". This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in a protein, known ...
What is the current status of trial NCT04387071?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-04-29. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT04387071?
The interventions under investigation include: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 (BIOLOGICAL), VLP-encapsulated TLR9 Agonist CMP-001 (DRUG).
Who is sponsoring clinical trial NCT04387071?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.